# Neo-KAN (NCT05472623)

> Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05472623
- Phase: PHASE2
- Status: WITHDRAWN
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Conditions: Resectable Non-Small Cell Lung Cancer
- Interventions: Adagrasib; Adagrasib/Nivolumab
- Enrollment: 0
- Primary outcome: Pathologic complete response (pCR) rate

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=neo-kan-nct05472623